RXO Analyst Ratings
RXO Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/16/2023 | -11.62% | Stifel | $19 → $17 | Maintains | Hold |
10/11/2023 | -16.82% | JP Morgan | $17 → $16 | Downgrades | Neutral → Underweight |
10/03/2023 | -32.41% | Susquehanna | $14 → $13 | Maintains | Negative |
10/02/2023 | -6.42% | Morgan Stanley | $20 → $18 | Maintains | Equal-Weight |
08/31/2023 | -27.22% | Susquehanna | $19 → $14 | Downgrades | Neutral → Negative |
08/07/2023 | 24.77% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform |
08/03/2023 | 3.98% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight |
08/03/2023 | -1.22% | Stephens & Co. | $23 → $19 | Maintains | Equal-Weight |
07/12/2023 | -1.22% | Wolfe Research | → $19 | Downgrades | Peer Perform → Underperform |
07/06/2023 | 3.98% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight |
06/09/2023 | 3.98% | Susquehanna | → $20 | Initiates Coverage On | → Neutral |
05/24/2023 | 40.37% | Barclays | → $27 | Initiates Coverage On | → Overweight |
05/04/2023 | 9.18% | Wells Fargo | $22 → $21 | Maintains | Equal-Weight |
04/04/2023 | — | Benchmark | Initiates Coverage On | → Hold | |
02/27/2023 | 14.37% | Cowen & Co. | → $22 | Initiates Coverage On | → Market Perform |
02/09/2023 | 19.57% | UBS | $20 → $23 | Maintains | Neutral |
02/09/2023 | 14.37% | Goldman Sachs | $20 → $22 | Maintains | Neutral |
02/09/2023 | 24.77% | Oppenheimer | $21 → $24 | Maintains | Outperform |
02/08/2023 | 3.98% | Stephens & Co. | → $20 | Maintains | Equal-Weight |
01/11/2023 | -11.62% | Stifel | $20 → $17 | Downgrades | Buy → Hold |
01/09/2023 | -1.22% | JP Morgan | → $19 | Initiates Coverage On | → Neutral |
12/20/2022 | -6.42% | Wells Fargo | → $18 | Initiates Coverage On | → Equal-Weight |
12/09/2022 | 3.98% | UBS | → $20 | Initiates Coverage On | → Neutral |
12/09/2022 | 3.98% | Morgan Stanley | → $20 | Initiates Coverage On | → Equal-Weight |
12/06/2022 | 29.97% | Jefferies | → $25 | Initiates Coverage On | → Buy |
12/05/2022 | — | Raymond James | Initiates Coverage On | → Market Perform | |
11/30/2022 | 14.37% | B of A Securities | → $22 | Initiates Coverage On | → Buy |
11/22/2022 | 9.18% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
11/22/2022 | 3.98% | Goldman Sachs | → $20 | Initiates Coverage On | → Neutral |
11/21/2022 | 40.37% | Vertical Research | → $27 | Initiates Coverage On | → Buy |
11/10/2022 | — | Wolfe Research | Initiates Coverage On | → Peer Perform | |
11/04/2022 | 3.98% | Stifel | → $20 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
10/16/2023 | -11.62% | Stifel | $19→$17 | 维护 | 保持 |
2023年10月11日 | -16.82% | 摩根大通 | $17→$16 | 评级下调 | 中性→减持 |
10/03/2023 | -32.41% | 萨斯奎哈纳 | $14→$13 | 维护 | 负性 |
10/02/2023 | -6.42% | 摩根士丹利 | $20→$18 | 维护 | 等重 |
2023年08月31日 | -27.22% | 萨斯奎哈纳 | $19→$14 | 评级下调 | 中性→阴性 |
08/07/2023 | 24.77% | 奥本海默 | →$24 | 重申 | 跑赢→跑赢大盘 |
08/03/2023 | 3.98% | 摩根士丹利 | $20→$20 | 重申 | 等重→等重 |
08/03/2023 | -1.22% | 斯蒂芬斯公司 | $23→$19 | 维护 | 等重 |
07/12/2023 | -1.22% | 沃尔夫研究 | →$19 | 评级下调 | 同行执行→表现不佳 |
07/06/2023 | 3.98% | 摩根士丹利 | $20→$20 | 重申 | 等重→等重 |
06/09/2023 | 3.98% | 萨斯奎哈纳 | →$20 | 开始承保 | →中性 |
2023年05月24日 | 40.37% | 巴克莱 | →$27 | 开始承保 | →超重 |
05/04/2023 | 9.18% | 富国银行 | $22→$21 | 维护 | 等重 |
04/04/2023 | - | 基准 | 开始承保 | →保留 | |
02/27/2023 | 14.37% | 考恩公司 | →$22 | 开始承保 | →市场表现 |
02/09/2023 | 19.57% | 瑞银集团 | $20→$23 | 维护 | 中性 |
02/09/2023 | 14.37% | 高盛 | $20→$22 | 维护 | 中性 |
02/09/2023 | 24.77% | 奥本海默 | $21→$24 | 维护 | 跑赢大盘 |
02/08/2023 | 3.98% | 斯蒂芬斯公司 | →$20 | 维护 | 等重 |
2023年1月11日 | -11.62% | Stifel | $20→$17 | 评级下调 | 购买→Hold |
01/09/2023 | -1.22% | 摩根大通 | →$19 | 开始承保 | →中性 |
12/20/2022 | -6.42% | 富国银行 | →$18 | 开始承保 | →等重 |
12/09/2022 | 3.98% | 瑞银集团 | →$20 | 开始承保 | →中性 |
12/09/2022 | 3.98% | 摩根士丹利 | →$20 | 开始承保 | →等重 |
12/06/2022 | 29.97% | 杰富瑞 | →$25 | 开始承保 | →购买 |
12/05/2022 | - | 雷蒙德·詹姆斯 | 开始承保 | →市场表现 | |
2022年11月30日 | 14.37% | B of A证券 | →$22 | 开始承保 | →购买 |
2022年11月22日 | 9.18% | 奥本海默 | →$21 | 开始承保 | →跑赢大盘 |
2022年11月22日 | 3.98% | 高盛 | →$20 | 开始承保 | →中性 |
2022年11月21日 | 40.37% | 垂直研究 | →$27 | 开始承保 | →购买 |
2022年11月10日 | - | 沃尔夫研究 | 开始承保 | →对等性能 | |
11/04/2022 | 3.98% | Stifel | →$20 | 开始承保 | →购买 |
What is the target price for RXO (RXO)?
RXO的目标价是多少?
The latest price target for RXO (NYSE: RXO) was reported by Stifel on October 16, 2023. The analyst firm set a price target for $17.00 expecting RXO to fall to within 12 months (a possible -11.62% downside). 32 analyst firms have reported ratings in the last year.
Stifel于2023年10月16日报道了RXO(纽约证券交易所代码:RXO)的最新目标价。这家分析公司将目标价定为17.00美元,预计RXO将在12个月内降至(可能下跌11.62%)。去年有32家分析公司公布了评级。
What is the most recent analyst rating for RXO (RXO)?
分析师对RXO的最新评级是多少?
The latest analyst rating for RXO (NYSE: RXO) was provided by Stifel, and RXO maintained their hold rating.
RXO(纽约证券交易所代码:RXO)的最新分析师评级由Stifel提供,RXO维持其持有评级。
When is the next analyst rating going to be posted or updated for RXO (RXO)?
RXO(RXO)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RXO, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RXO was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公开财务报表,与RXO的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。RXO的上一次评级是在2023年10月16日提交的,所以你应该预计下一次评级将在2024年10月16日左右提供。
Is the Analyst Rating RXO (RXO) correct?
分析师评级RXO(RXO)正确吗?
While ratings are subjective and will change, the latest RXO (RXO) rating was a maintained with a price target of $19.00 to $17.00. The current price RXO (RXO) is trading at is $19.24, which is out of the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的RXO(RXO)评级维持不变,目标价在19.00美元至17.00美元之间。RXO目前的交易价格为19.24美元,超出了分析师的预测区间。